Waters/$WAT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Waters
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.
Ticker
$WAT
Sector
Primary listing
NYSE
Employees
7,600
Headquarters
Website
Waters Metrics
BasicAdvanced
$20B
29.62
$11.09
1.04
-
Price and volume
Market cap
$20B
Beta
1.04
52-week high
$423.56
52-week low
$275.05
Average daily volume
684K
Financial strength
Current ratio
1.754
Quick ratio
1.08
Long term debt to equity
60.491
Total debt to equity
67.458
Interest coverage (TTM)
10.77%
Profitability
EBITDA (TTM)
1,055.442
Gross margin (TTM)
59.02%
Net profit margin (TTM)
21.71%
Operating margin (TTM)
28.18%
Effective tax rate (TTM)
16.40%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
11.70%
Return on equity (TTM)
37.03%
Valuation
Price to earnings (TTM)
29.624
Price to revenue (TTM)
6.407
Price to book
9.05
Price to tangible book (TTM)
80.5
Price to free cash flow (TTM)
31.51
Free cash flow yield (TTM)
3.17%
Free cash flow per share (TTM)
10.422
Growth
Revenue change (TTM)
5.89%
Earnings per share change (TTM)
10.77%
3-year revenue growth (CAGR)
1.64%
10-year revenue growth (CAGR)
4.13%
3-year earnings per share growth (CAGR)
-1.17%
10-year earnings per share growth (CAGR)
7.18%
What the Analysts think about Waters
Analyst ratings (Buy, Hold, Sell) for Waters stock.
Bulls say / Bears say
Waters posted Q2 2025 revenue of $771.3 million, a 9% increase that surpassed Street forecasts and led management to raise the lower end of full-year adjusted EPS guidance to $12.95 (Reuters)
The planned merger with BD’s Biosciences & Diagnostics division will double Waters’ total addressable market to $40 billion and strengthen its recurring revenue streams through expanded bioseparations and diagnostic offerings (Reuters)
Management attributed the upward revision in guidance partly to growth vectors such as GLP-1 analysis, PFAS testing, and generics, highlighting rapid uptake of new products in high-growth areas (Reuters)
Academic & Government sales declined 3% in Q2 2025 on a constant-currency basis, reflecting persistent funding volatility and potential headwinds from proposed research budget cuts (Reuters)
Analysts warn the $17.5 billion merger with BD’s Biosciences & Diagnostics arm is a high-priced deal with a weaker business that could face complex integration challenges, raising execution risk (Reuters)
Waters’ stock dropped 5.8% on the BD merger announcement, signaling investor skepticism over dilution and the near-term accretion of the reverse Morris Trust structure (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
Waters Financial Performance
Revenues and expenses
Waters Earnings Performance
Company profitability
Waters News
AllArticlesVideos
WATERS CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Waters Corporation - WAT
Business Wire3 months ago
Top Stock Movers Now: Autodesk, Fortinet, Waters, and More
Investopedia3 months ago
Waters and BD Biosciences & Diagnostic Solutions announce $17.5B merger
Proactive Investors3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Waters stock?
Waters (WAT) has a market cap of $20B as of October 06, 2025.
What is the P/E ratio for Waters stock?
The price to earnings (P/E) ratio for Waters (WAT) stock is 29.62 as of October 06, 2025.
Does Waters stock pay dividends?
No, Waters (WAT) stock does not pay dividends to its shareholders as of October 06, 2025.
When is the next Waters dividend payment date?
Waters (WAT) stock does not pay dividends to its shareholders.
What is the beta indicator for Waters?
Waters (WAT) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.